Navigation Links
Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares
Date:10/20/2011

inciples in the United States.

The GAAP financial measure most directly comparable to adjusted net income is GAAP net income and the GAAP financial measure most directly comparable to adjusted net income per share is GAAP net income per share. To calculate regional and divisional revenue growth rates that exclude the impact of changes in foreign currency exchange rates, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The GAAP financial measure most directly comparable to this non-GAAP financial measure is growth rate percentages using net sales on a GAAP basis. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in the Company's business, to assess its performance relative to its competitors, and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of the Company's operating segments. The adjustments excluded from the Company's non-GAAP financial measures are consistent with those excluded from its reportable segments' measure of profit or loss. These adjustments are excluded from the segment measures that are reported to the Company's chief operating decision maker and are used to make operating decisions and assess performance.

The Company believes that presenting adjusted net income, adjusted net income per share and regional and divisional revenue growth rates that exclude the impact of changes in foreign currency exchange rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by Boston Scie
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Boston Scientific Completes Enrollment in Benign Stricture Study of WallFlex® Biliary RX Stent
2. Boston Scientific Launches Promus Element™ Stent System In China
3. Boston Scientific Welcomes Introduction of Medical Device Regulatory Improvement Act in U.S. Senate
4. Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results
5. COPAN WASP® Lands at Prestigious Boston Medical Center
6. Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial
7. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent
8. Bluestar Silicones to Present Antimicrobial Silicones at Medical Silicones Conference in Boston
9. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
10. Boston Scientific Launches Coyote™ Balloon Catheter
11. Boston Scientific Sponsors New Patient Portal Dedicated to Pelvic Floor Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- In the Friday, December 19 edition of USA ... Technology (HIT) features Konica Minolta, the company announced today. The supplement ... leading healthcare organizations. In addition to the print ... as New York , Chicago ... Minneapolis and San Francisco ...
(Date:12/19/2014)... 19, 2014 TODAY, AEGATE, the ... World announced the appointment of Peter Fox ... Chief Channels and Partner Officer. Peter has ... to its acquisition by Oracle in 2011. ... Geneva and subsequently Convergys, a world ...
(Date:12/19/2014)... , Dec. 19, 2014  Newport Corporation (NASDAQ: ... Kadia, Ph.D. has joined the company,s Board of ... Officer and a director of Evans Analytical Group, ... evaluation and analytical services to companies in a ... to joining Evans Analytical Group, Dr. Kadia spent ...
Breaking Medicine Technology:USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... Amarin Corporation plc (Nasdaq: AMRN ) ... on cardiovascular disease, today announced that, in connection with ... Shares ("ADSs"), the underwriters of the offering have exercised ... aggregate of 1,800,000 additional ADSs to cover over-allotments.  The ...
... 7, 2011 Echo Therapeutics, Inc. (OTC Bulletin Board: ... Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous ... transdermal drug delivery, today announced that Patrick T. Mooney, ... Echo Therapeutics will present at the OneMedForum 2011 annual ...
Cached Medicine Technology:Amarin Announces Underwriters' Exercise of Over-Allotment Option 2Amarin Announces Underwriters' Exercise of Over-Allotment Option 3Amarin Announces Underwriters' Exercise of Over-Allotment Option 4Echo Therapeutics to Present at the OneMedForum 2011 Conference 2
(Date:12/19/2014)... The Plantrician Project , a ... tools and resources for healthcare professionals and their ... world’s leading online cooking school, have joined forces ... Culinary Rx. As an online food and nutrition ... for debut spring 2015, will be designed to ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Eufaula, Oklahoma, ... to Lake Eufaula, the state’s largest lake with more ... town is home to a little more than 3,000 ... P.M. on Saturday, the 6th of December. , Featuring ... way through downtown Eufaula on Main Street. Narconon ...
(Date:12/19/2014)... Abilene, TX (PRWEB) December 20, 2014 ... XC, a new injectable filler from respected cosmetic brand ... can occur naturally with age. The Medspa at Hendrick ... new development in skin care technology to its clients. ... filler gel to be FDA-approved to treat the mid-face ...
(Date:12/19/2014)... The intestinal bacteria that cause inflammatory bowel disease, which ... researchers report. The findings, published recently in the ... to prevent the disease and treat the 1.6 million ... "The intestinal bacteria, or ,gut microbiome, you develop ... impact on your health for the rest of your ...
(Date:12/19/2014)... -- Injectable drug users who also use cocaine and ... other substance users, a new study finds. "We ... of suicide attempt and completed suicide," Didier Jutras-Aswad, a ... a university news release. "However, there are many different ... among substance users were actually more likely to attempt ...
Breaking Medicine News(10 mins):Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2
... In keeping with its,commitment to wellness, and following ... Michigan, a leading HMO in the state, is building ... employees at the,workplace., BCN, which is the HMO ... year instituted Wellness Works!, an employee health,and fitness program ...
... Larry Kocot and Robert,Seidman Headline Agenda at FDA/CMS ... medicine has,progressed beyond a topic of industry insider ... public and private payers. Value isn,t a new,concept ... mean for buying and,selling biopharmaceuticals? How is value ...
... FDA Approval, Agreement will Broaden Access to ... Cholesterol-Reducing Medicine, ... USA (GSK) and Merck & Co., Inc.,Whitehouse Station, NJ, USA ... over-the-counter (OTC) marketing rights for,MEVACOR(R) (lovastatin). Under the agreement, GSK ...
... N.J., Nov. 26 Pharmasset, Inc.,(Nasdaq: VRUS ... President,Marketing & Sales, responsible for coordinating the global ... Mr. Higgins, who,has served as a consultant to ... Marketing, Virology at Hoffmann-LaRoche, Inc. His areas,of expertise ...
... also hinder progress, study finds , MONDAY, Nov. 26 ... ("good") cholesterol increase the risk of memory problems and ... , The study also found that high levels of ... meat, also boosts post-stroke disability. , "People with low ...
... prevent osteoporosis, researchers say , , MONDAY, Nov. 26 (HealthDay News) ... than do non-depressed women in the same age range, a ... pronounced in certain regions of the hip, which is troubling ... -- and potentially fatal -- consequences of osteoporosis. , ...
Cached Medicine News:Health News:Leading by Example: Blue Care Network of Michigan Shows How Employers Can Improve Employee Wellness 2Health News:Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace 2Health News:Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace 3Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 3Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 4Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 5Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 6Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 7Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 8Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 9Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 10Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 11Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 12Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 13Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 14Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 15Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 16Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 17Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 18Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 19Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 20Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 21Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 22Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 23Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 24Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 25Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 26Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 27Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 28Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 29Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 30Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 31Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 32Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 33
0.3 mm diameter hemi-ball tip....
ICL manipulator with textured micro-ball tip....
Vaulted shank. For engaging the inferior haptic without touching the dome of the IOL....
... ophthalmoscopes are individually adjusted for perfect focus ... not on paper. This, along with Keeler's ... ensures that whatever the patient's pupil size, ... field of view. Lithium-ion technology provides a ...
Medicine Products: